Literature DB >> 4845674

Pharmacokinetics of cycloserine and terizidone. A comparative study.

L Zítková, J Tousek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4845674     DOI： 10.1159/000221787

Source DB:  PubMed          Journal:  Chemotherapy        ISSN： 0009-3157            Impact factor:   2.544


× No keyword cloud information.
  13 in total

1.  d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Authors:  Devyani Deshpande; Jan-Willem C Alffenaar; Claudio U Köser; Keertan Dheda; Moti L Chapagain; Noviana Simbar; Thomas Schön; Marieke G G Sturkenboom; Helen McIlleron; Pooi S Lee; Thearith Koeuth; Stellah G Mpagama; Sayera Banu; Suporn Foongladda; Oleg Ogarkov; Suporn Pholwat; Eric R Houpt; Scott K Heysell; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

2.  Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India.

Authors:  Agibothu Kupparam Hemanth Kumar; Alok Kumar; Thiruvengadam Kannan; Rakesh Bhatia; Dipti Agarwal; Santosh Kumar; Rajeshwar Dayal; Sheo Pratap Singh; Geetha Ramachandran
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

3.  Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis.

Authors:  Mwila Mulubwa; Pierre Mugabo
Journal:  Br J Clin Pharmacol       Date:  2019-07-12       Impact factor: 4.335

4.  Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.

Authors:  Y Dong; X Zhao; B N Kreiswirth; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 5.  Safety and tolerability profile of second-line anti-tuberculosis medications.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

6.  Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa.

Authors:  Martha L van der Walt; Karen Shean; Piet Becker; Karen H Keddy; Joey Lancaster
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

7.  Cycloserine as a urinary tract antiseptic.

Authors:  P Kaltenis
Journal:  Int Urol Nephrol       Date:  1986       Impact factor: 2.370

8.  Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone.

Authors:  Maxwell T Chirehwa; Richard Court; Mariana de Kock; Lubbe Wiesner; Nihal de Vries; Joseph Harding; Tawanda Gumbo; Gary Maartens; Rob Warren; Paolo Denti; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

10.  Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study.

Authors:  Zhengchao Dong; Michael F Grunebaum; Martin J Lan; Vashti Wagner; Tse-Hwei Choo; Matthew S Milak; Tarek Sobeih; J John Mann; Joshua T Kantrowitz
Journal:  Front Psychiatry       Date:  2021-06-02       Impact factor: 4.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.